Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2 as a possible risk factor in rectal cancer progression
ISRCTN12078175Phase 2Suspended
- Sponsor
- Research Institute of Virology, Ministry of Health of Uzbekistan
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ribavirin, dexamethasone and glucose in rectal cancer (2 arms), sponsored by Research Institute of Virology, Ministry of Health of Uzbekistan. Primary endpoint: Overall treatment outcome based on absence of recurrence. Started Dec 2024; status: suspended.
02
Drugs
ribavirindexamethasoneglucose
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ISRCTN12078175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12078175.